135 related articles for article (PubMed ID: 35687484)
1. TPO antibody status prior to first radioactive iodine therapy as a predictive parameter for hypothyroidism in Graves' disease.
Verdickt S; Van Nes F; Moyson C; Maes T; Van Crombrugge P; Van den Bruel A; Decallonne B
Eur Thyroid J; 2022 Aug; 11(4):. PubMed ID: 35687484
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting timing of hypothyroidism following radioactive iodine therapy (RAIT) for patients with Graves' disease: A 12-month observational study.
Mahmoud HA; Alsanory AAAA; Mostafa HG; Hassan ER
Nucl Med Commun; 2024 Jun; 45(6):499-509. PubMed ID: 38586956
[TBL] [Abstract][Full Text] [Related]
3. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
5. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
[TBL] [Abstract][Full Text] [Related]
6. Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Lu JY; Chen KH; Shih SR; Wen FY; Wu WC; Chen TC; Hu FC
Endocr Pract; 2023 Feb; 29(2):89-96. PubMed ID: 36396015
[TBL] [Abstract][Full Text] [Related]
7. Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period.
Kaplowitz PB; Jiang J; Vaidyanathan P
J Pediatr Endocrinol Metab; 2020 Mar; 33(3):383-389. PubMed ID: 31603857
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant lithium improves the efficacy of radioactive iodine treatment in Graves' and toxic nodular disease.
Martin NM; Patel M; Nijher GM; Misra S; Murphy E; Meeran K
Clin Endocrinol (Oxf); 2012 Oct; 77(4):621-7. PubMed ID: 22443227
[TBL] [Abstract][Full Text] [Related]
9. Influence of high tissue-absorbed dose on anti-thyroid antibodies in radioiodine therapy of Graves' disease patients.
Listewnik MH; Piwowarska-Bilska H; Jasiakiewicz K; Birkenfeld B
Adv Clin Exp Med; 2021 Sep; 30(9):913-921. PubMed ID: 34418335
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of radioactive iodine treatment of graves' hyperthyroidism using a single calculated
Wong KK; Shulkin BL; Gross MD; Avram AM
Clin Diabetes Endocrinol; 2018; 4():20. PubMed ID: 30505461
[TBL] [Abstract][Full Text] [Related]
11. Transient Hypothyroidism after Radioiodine for Graves' Disease: Challenges in Interpreting Thyroid Function Tests.
Sheehan MT; Doi SA
Clin Med Res; 2016 Mar; 14(1):40-5. PubMed ID: 26864507
[TBL] [Abstract][Full Text] [Related]
12. Cure Rates After a Single Dose of Radioactive Iodine to Treat Hyperthyroidism: The Fixed-Dose Regimen.
Madu NM; Skinner C; Oyibo SO
Cureus; 2022 Aug; 14(8):e28316. PubMed ID: 36039121
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves' disease patients.
Hu RT; Liu DS; Li B
BMC Endocr Disord; 2020 May; 20(1):76. PubMed ID: 32471411
[TBL] [Abstract][Full Text] [Related]
14. Thyroid peroxidase activity-inhibiting immunoglobulins in patients with autoimmune thyroid disease.
Okamoto Y; Hamada N; Saito H; Ohno M; Noh J; Ito K; Morii H
J Clin Endocrinol Metab; 1989 Apr; 68(4):730-4. PubMed ID: 2921308
[TBL] [Abstract][Full Text] [Related]
15. Thyroid Isthmus Length and Iodine Turnover as Predictors of Successful Radioactive Iodine Therapy in Patients with Graves' Disease.
Park SH; Hwang S; Han S; Shin DY; Lee EJ
Int J Endocrinol; 2017; 2017():7354673. PubMed ID: 29358949
[TBL] [Abstract][Full Text] [Related]
16. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine treatment outcomes in thyroid glands previously irradiated for Graves' hyperthyroidism.
Leslie WD; Peterdy AE; Dupont JO
J Nucl Med; 1998 Apr; 39(4):712-6. PubMed ID: 9544686
[TBL] [Abstract][Full Text] [Related]
18. Radioactive Iodine: A Living History.
Daniels GH; Ross DS
Thyroid; 2023 Jun; 33(6):666-673. PubMed ID: 37307104
[No Abstract] [Full Text] [Related]
19. Predictive value of pyramidal lobe, percentage thyroid uptake and age for ablation outcome after 15 mCi fixed dose of radioiodine-131 in Graves' disease.
Zaman MU; Fatima N; Zaman U; Sajjad Z; Zaman A; Tahseen R
Indian J Nucl Med; 2015; 30(4):309-13. PubMed ID: 26430313
[TBL] [Abstract][Full Text] [Related]
20. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.
Kahaly GJ; Bartalena L; Hegedüs L; Leenhardt L; Poppe K; Pearce SH
Eur Thyroid J; 2018 Aug; 7(4):167-186. PubMed ID: 30283735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
